title: Development of new-onset psoriasis while on anti-TNFalpha treatment.
authors.forename: C
authors.initials: C
authors.lastname: Matthews
authors.forename: S
authors.initials: S
authors.lastname: Rogers
authors.forename: O
authors.initials: O
authors.lastname: FitzGerald
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab